The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Human CD14+CTLA-4+ Regulatory Dendritic Cells Suppress T-Cell Response by Cytotoxic T-Lymphocyte Antigen-4-Dependent IL-10 and Indoleamine-2,3-Dioxygenase Production in Hepatocellular Carcinoma
Open accessAbstract
Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide with limited therapeutic options. HCC-induced immunosuppression often leads to ineffectiveness of immuno-promoting therapies. Currently, suppressing the suppressors has become the potential strategy for cancer immunotherapy. So, figuring out the immunosuppressive mechanisms induced and employed by HCC will be helpful to the design and application of HCC immunotherapy. Here, we identified one new subset of human CD14+CTLA-4+ regulatory dendritic cells (CD14+DCs) in HCC patients, representing ˜13% of peripheral blood mononuclear cells. CD14+DCs significantly suppress T-cell response in vitro through interleukin (IL)-10 and indoleamine-2,3-dioxygenase (IDO). Unexpectedly, CD14+DCs expressed high levels of cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1, and CTLA-4 was found to be essential to IL-10 and IDO production. So, we identified a novel human tumor-induced regulatory DC subset, which suppresses antitumor immune response through CTLA-4-dependent IL-10 and IDO production, thus indicating the important role of nonregulatory T-cell-derived CTLA-4 in tumor-immune escape or immunosuppression. Conclusions : These data outline one mechanism for HCC to induce systemic immunosuppression by expanding CD14+DCs, which may contribute to HCC progression. This adds new insight to the mechanism for HCC-induced immunosuppression and may also provide a previously unrecognized target of immunotherapy for HCC. (Hepatology 2014;59:567–579)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
CTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956
Regulatory T cells: mechanisms of differentiation and function
Josefowicz, S. Z., Lu, L.-F., & Rudensky, A. Y. (2012) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141623 · Cited by 2,866
Ido expression by dendritic cells: tolerance and tryptophan catabolism
Mellor, A. L., & Munn, D. H. (2004) · Nature Reviews Immunology · doi:10.1038/nri1457 · Cited by 2,341
B cells regulate autoimmunity by provision of IL-10
Fillatreau, S., Sweenie, C. H., McGeachy, M. J., Gray, D., & Anderton, S. M. (2002) · Nature Immunology · doi:10.1038/ni833 · Cited by 1,647
Indoleamine 2,3 dioxygenase and metabolic control of immune responses
Munn, D. H., & Mellor, A. L. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.10.001 · Cited by 1,037
Research works printed but not linked: 35
- Rabinovich, 2007, Immunosuppressive strategies that are mediated by tumor cells., Annu Rev Immunol, 25, 267, 10.1146/annurev.immunol.25.022106.141609 · DOI · Paper page
- Zou, 2006, Regulatory T cells, tumour immunity and immunotherapy., Nat Rev Immunol, 6, 295, 10.1038/nri1806 · DOI · Paper page
- Wang, 2007, Regulatory T cells and cancer., Curr Opin Immunol, 19, 217, 10.1016/j.coi.2007.02.004 · DOI · Paper page
- Vignali, 2008, How regulatory T cells work., Nat Rev Immunol, 8, 523, 10.1038/nri2343 · DOI · Paper page
- von Boehmer, 2005, Mechanisms of suppression by suppressor T cells., Nat Immunol, 6, 338, 10.1038/ni1180 · DOI · Paper page
- Han, 2009, CD69CD4CD25 T cells, a new subset of regulatory T cells, suppress T cell proliferation through membranebound TGF1., J Immunol, 182, 111, 10.4049/jimmunol.182.1.111 · DOI · Paper page
- Mantovani, 2010, Macrophages, innate immunity and cancer: balance, tolerance, and diversity., Curr Opin Immunol, 22, 231, 10.1016/j.coi.2010.01.009 · DOI · Paper page
- Auffray, 2009, Blood monocytes: development, heterogeneity, and relationship with dendritic cells., Annu Rev Immunol, 27, 669, 10.1146/annurev.immunol.021908.132557 · DOI · Paper page
- Ueno, 2010, Harnessing human dendritic cell subsets for medicine., Immunol Rev, 234, 199, 10.1111/j.0105-2896.2009.00884.x · DOI · Paper page
- Bachem, 2010, Superior antigen crosspresentation and XCR1 expression define human CD11cCD141 cells as homologues of mouse CD8 dendritic cells., J Exp Med, 207, 1273, 10.1084/jem.20100348 · DOI · Paper page
- Kassianos, 2012, Human CD1c (BDCA1) myeloid dendritic cells secrete IL10 and display an immunoregulatory phenotype and function in response to Escherichia coli., Eur J Immunol, 42, 1512, 10.1002/eji.201142098 · DOI
- Qian, 2012, Naturally occurring CD1c human regulatory dendritic cells: immunoregulators that are expanded in response to E. coli infection., Eur J Immunol, 42, 1388, 10.1002/eji.201242632 · DOI
- Bamboat, 2009, Human liver dendritic cells promote T cell hyporesponsiveness., J Immunol, 184, 1901, 10.4049/jimmunol.0803404 · DOI · Paper page
- Chu, 2012, Resident CD141 (BDCA3) dendritic cells in human skin produce IL10 and induce regulatory T cells that suppress skin inflammation., J Exp Med, 209, 935, 10.1084/jem.20112583 · DOI · Paper page
- Morel, 2011, Dendritic cells and the maintenance of selftolerance., Immunol Res, 50, 124, 10.1007/s12026-011-8217-y · DOI
- Yogev, 2012, Dendritic cells ameliorate autoimmunity in the CNS by controlling the homeostasis of PD1 receptor regulatory T cells., Immunity, 37, 264, 10.1016/j.immuni.2012.05.025 · DOI · Paper page
- Liu, 2009, Tumoreducated CD11bhighIalow regulatory dendritic cells suppress T cell response through arginase I., J Immunol, 182, 6207, 10.4049/jimmunol.0803926 · DOI · Paper page
- Breous, 2011, Potential of immunotherapy for hepatocellular carcinoma., J Hepatol, 54, 830, 10.1016/j.jhep.2010.10.013 · DOI
- Zhou, 2009, Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients., Int J Cancer, 125, 1640, 10.1002/ijc.24556 · DOI · Paper page
- Li, 2009, Cancerexpanded myeloidderived suppressor cells induce anergy of NK Cells through membranebound TGF1., J Immunol, 182, 240, 10.4049/jimmunol.182.1.240 · DOI · Paper page
- Grossman, 2004, Human T regulatory cells can use the perforin pathway to cause autologous target cell death., Immunity, 21, 589, 10.1016/j.immuni.2004.09.002 · DOI · Paper page
- Xia, 2008, Hepatic microenvironment programs hematopoietic progenitor differentiation into regulatory dendritic cells, maintaining liver tolerance., Blood, 112, 3175, 10.1182/blood-2008-05-159921 · DOI
- Agrawal, 2006, ERK1 mice exhibit Th1 cell polarization and increased susceptibility to experimental autoimmune encephalomyelitis., J Immunol, 176, 5788, 10.4049/jimmunol.176.10.5788 · DOI
- Kaiser, 2009, TPL2 negatively regulates interferon production in macrophages and myeloid dendritic cells., J Exp Med, 206, 1863, 10.1084/jem.20091059 · DOI · Paper page
- Pizzolla, 2011, CD68expressing cells can prime T cells and initiate autoimmune arthritis in the absence of reactive oxygen species., Eur J Immunol, 41, 403, 10.1002/eji.201040598 · DOI
- Saraiva, 2010, The regulation of IL10 production by immune cells., Nat Rev Immunol, 10, 170, 10.1038/nri2711 · DOI · Paper page
- Mauri, 2012, Immune regulatory function of B cells., Annu Rev Immunol, 30, 221, 10.1146/annurev-immunol-020711-074934 · DOI · Paper page
- Munn, 2007, Indoleamine 2,3dioxygenase and tumorinduced tolerance., J Clin Invest, 117, 1147, 10.1172/JCI31178 · DOI · Paper page
- Katz, 2008, Indoleamine 2,3dioxygenase in Tcell tolerance and tumoral immune escape., Immunol Rev, 222, 206, 10.1111/j.1600-065X.2008.00610.x · DOI · Paper page
- Vignali, 2008, How regulatory T cells work., Nat Rev Immunol, 8, 523, 10.1038/nri2343 · DOI · Paper page
- Fallarino, 2003, Modulation of tryptophan catabolism by regulatory T cells., Nat Immunol, 4, 1206, 10.1038/ni1003 · DOI · Paper page
- File, 2008, Control of peripheral Tcell tolerance and autoimmunity via the CTLA4 and PD1 pathways., Immunol Rev, 224, 166, 10.1111/j.1600-065X.2008.00662.x · DOI · Paper page
- Friedline, 2009, CD4 regulatory T cells require CTLA4 for the maintenance of systemic tolerance., J Exp Med, 206, 421, 10.1084/jem.20081811 · DOI · Paper page
- Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma., N Engl J Med, 363, 711, 10.1056/NEJMoa1003466 · DOI · Paper page
- Munn, 2004, Ligation of B7-1B7-2 by human CD4 T cells triggers indoleamine 2,3dioxygenase activity in dendritic cells., J Immunol, 172, 4100, 10.4049/jimmunol.172.7.4100 · DOI · Paper page
Cited by
Immunotherapies for hepatocellular carcinoma
Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00573-2 · Cited by 1,843
Advances in immunotherapy for hepatocellular carcinoma
Sangro, B., Sarobe, P., Hervás-Stubbs, S., & Melero, I. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00438-0 · Cited by 1,306
Immunological landscape and immunotherapy of hepatocellular carcinoma
Prieto, J., Melero, I., & Sangro, B. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.173 · Cited by 566
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
Schildberg, F. A., Klein, S. R., Freeman, G. J., & Sharpe, A. H. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.002 · Cited by 542
Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review
Oura, K., Morishita, A., Tani, J., & Masaki, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115801 · Cited by 426
Lu, C., Rong, D., Zhang, B., Zheng, W., Wang, X., Chen, Z., & Tang, W. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1047-6 · Cited by 418
Self-citationImmunosuppressive cells in tumor immune escape and metastasis
Liu, Y., & Cao, X. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1376-x · Cited by 400
Self-citationFu, Y., Liu, S., Zeng, S., & Shen, H. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1396-4 · Cited by 390
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Yarchoan, M., Singal, A. G., Marron, T. U., Schwartz, M., Pikarsky, E., Kudo, M., & Finn, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00868-0 · Cited by 391
Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma
Chen, C., Wang, Z., Ding, Y., & Qin, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1133308 · Cited by 305
Current and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review
Daher, S., Massarwa, M., Benson, A. A., & Khoury, T. (2018) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2017.00031 · Cited by 304
Role of nonresolving inflammation in hepatocellular carcinoma development and progression
Yu, L.-X., Ling, Y., & Wang, H.-Y. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0048-z · Cited by 301
CTLA-4: From mechanism to autoimmune therapy
Hosseini, A., Gharibi, T., Marofi, F., Babaloo, Z., & Baradaran, B. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106221 · Cited by 297
The yin and yang of evasion and immune activation in HCC
Makarova-Rusher, O. V., Medina-Echeverz, J., Duffy, A. G., & Greten, T. F. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.038 · Cited by 293
The origin and function of tumor-associated macrophages
Liu, Y., & Cao, X. (2015) · Cellular & Molecular Immunology · doi:10.1038/cmi.2014.83 · Cited by 291
Self-citationCheng, J.-T., Deng, Y.-N., Yi, H.-M., Wang, G.-Y., Fu, B.-S., Chen, W.-J., Liu, W., Tai, Y., Peng, Y.-W., & Zhang, Q. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.7 · Cited by 267
Fibroblast heterogeneity in tumor micro-environment: Role in immunosuppression and new therapies
Mhaidly, R., & Mechta-Grigoriou, F. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101417 · Cited by 259
Yu, X., Yang, F., Shen, Z., Zhang, Y., Sun, J., Qiu, C., Zheng, Y., Zhao, W., Yuan, S., Zeng, D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46047-8 · Cited by 47
Metadata
- Authors
- Han, Y., Chen, Z., Yang, Y., Jiang, Z., Gu, Y., Liu, Y., Lin, C., Pan, Z., Yu, Y., Jiang, M., Zhou, W., & Cao, X.
- Venue
- Hepatology
- Published
- 2014-02
- Volume
- 59
- Issue
- 2
- Pages
- 567-579
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2153267053
- Cited by
- 226
- References
- 6
- FWCI
- 6.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 577 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.